CTLA4, known for suppressing activated T cells and enhancing regulatory T cells (Treg) function47,48, and PD-1, critical in tumor immune escape by inhibiting immune cell activity via binding to tumor cell surface ligands49, suggest a relatively active tumor microenvironment in low-risk patients. This evidence concerns the gene PDCD1 and neoplasm.